Evofem Biosciences Business Summary

Evofem Biosciences, Inc. (EVFM) is a commercial-stage biopharmaceutical company that generates revenue primarily through the transaction-based sale of its two FDA-approved products: Phexxi, a hormone-free, on-demand contraceptive vaginal gel, and SOLOSEC, a single-dose oral antibiotic for bacterial vaginosis and trichomoniasis. The company’s business model is centered on women’s sexual and reproductive health, with revenue streams further diversified through international licensing agreements, such as its 2026 commercialization launch in the United Arab Emirates, and a diagnostic collaboration with Aditxt to market Mitomic tests for endometriosis and ovarian cancer. Evofem competes directly with players like Sebela Pharmaceuticals, TherapeuticsMD, and Dare Bioscience. While these competitors often focus on traditional hormonal therapies, Evofem occupies a distinct niche as the leader in non-hormonal, on-demand prescription contraception, currently operating on the over-the-counter market with a strategic focus on regaining a national exchange listing and achieving positive EBITDA by 2027. The leadership team is anchored by CEO, President, and Executive Director Saundra Pelletier, who has spearheaded the company’s growth since 2015, including the landmark FDA approval of Phexxi and the strategic acquisition of SOLOSEC. Pelletier is supported by Chief Financial Officer Ivy Zhang, a seasoned finance executive with over 14 years of experience in the pharmaceutical and medical device industries, and Kathy Gallo-Doyle, Senior Vice President of Commercial Operations, who oversees national sales and market access. The company’s Board of Directors features prominent industry figures, including Kim Kamdar, Ph.D., a Managing Partner at Domain Associates, and Tony O’Brien, the former Director General of Ireland’s Health Service Executive. Despite the termination of a proposed merger with Aditxt in late 2025, Evofem maintains strategic institutional backing from Domain Associates and continues to leverage its executive pedigree to navigate its independent path toward sustainable growth.